Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTGTQHC)

• DTT Name: DNA topoisomerase I (TOP1)
• Synonyms: DNA topoisomerase I
• Gene Name: TOP1
• DTT Type: Successful target; [1]
• BioChemical Class: Topoisomerase
• UniProt ID: TOP1_HUMAN
• TTD ID: T09826
• EC Number: EC 5.6.2.2
• Sequence:
  MSGDHLHNDSQIEADFRLNDSHKHKDKHKDREHRHKEHKKEKDREKSKHSNSEHKDSEKK
  HKEKEKTKHKDGSSEKHKDKHKDRDKEKRKEEKVRASGDAKIKKEKENGFSSPPQIKDEP
  EDDGYFVPPKEDIKPLKRPRDEDDADYKPKKIKTEDTKKEKKRKLEEEEDGKLKKPKNKD
  KDKKVPEPDNKKKKPKKEEEQKWKWWEEERYPEGIKWKFLEHKGPVFAPPYEPLPENVKF
  YYDGKVMKLSPKAEEVATFFAKMLDHEYTTKEIFRKNFFKDWRKEMTNEEKNIITNLSKC
  DFTQMSQYFKAQTEARKQMSKEEKLKIKEENEKLLKEYGFCIMDNHKERIANFKIEPPGL
  FRGRGNHPKMGMLKRRIMPEDIIINCSKDAKVPSPPPGHKWKEVRHDNKVTWLVSWTENI
  QGSIKYIMLNPSSRIKGEKDWQKYETARRLKKCVDKIRNQYREDWKSKEMKVRQRAVALY
  FIDKLALRAGNEKEEGETADTVGCCSLRVEHINLHPELDGQEYVVEFDFLGKDSIRYYNK
  VPVEKRVFKNLQLFMENKQPEDDLFDRLNTGILNKHLQDLMEGLTAKVFRTYNASITLQQ
  QLKELTAPDENIPAKILSYNRANRAVAILCNHQRAPPKTFEKSMMNLQTKIDAKKEQLAD
  ARRDLKSAKADAKVMKDAKTKKVVESKKKAVQRLEEQLMKLEVQATDREENKQIALGTSK
  LNYLDPRITVAWCKKWGVPIEKIYNKTQREKFAWAIDMADEDYEF
• Function: Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component ARNTL/BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the ARNTL/BMAL1 promoter. Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex.
• Reactome Pathway: SUMOylation of DNA replication proteins (R-HSA-4615885)

Molecular Interaction Atlas (MIA) of This DTT

5 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
B-Lactams	DMR8YD6	Bacterial infection	1A00-1C4Z	Approved	[2]
Belotecan hydrocholoride	DM3SRJZ	Small-cell lung cancer	2C25.Y	Approved	[3]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[4]
Topetecan	DMAE6LK	Small-cell lung cancer	2C25.Y	Approved	[1]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[4]

44 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[5]
Datopotamab deruxtecan	DMO4GTC	Breast cancer	2C60-2C65	Phase 3	[6]
Edotecarin	DM3ZL7D	Gastric adenocarcinoma	2B72	Phase 3	[7]
Etirinotecan pegol	DMQHX1Y	Breast cancer	2C60-2C65	Phase 3	[8]
Exatecan	DMCA7FN	Solid tumour/cancer	2A00-2F9Z	Phase 3	[9]
Karenitecin	DMCRGY4	Lung cancer	2C25.0	Phase 3	[10]
Rubitecan	DMDWU1S	Human immunodeficiency virus infection	1C62	Phase 3	[11]
9-AMINOCAMPTOTHECIN	DMQXYRG	Acquired immune deficiency syndrome	1C62.3	Phase 2	[12]
AR-67	DM8A71F	Glioblastoma multiforme	2A00.0	Phase 2	[13]
Beta-Lapachone	DMMI84K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[14]
CKD602	DMW9F1G	Solid tumour/cancer	2A00-2F9Z	Phase 2	[15]
CRLX101	DMQUWXY	Non-small-cell lung cancer	2C25.Y	Phase 2	[16]
DIFLOMOTECAN	DM20ATW	Solid tumour/cancer	2A00-2F9Z	Phase 2	[17]
EQ-917	DMD4YRG	Solid tumour/cancer	2A00-2F9Z	Phase 2	[18]
Gimatecan	DMSKMET	Breast cancer	2C60-2C65	Phase 2	[19]
LE-SN38	DMW50NF	Colorectal cancer	2B91.Z	Phase 2	[20]
Patritumab deruxtecan	DMNIAWS	Breast cancer	2C60-2C65	Phase 2	[21]
PEG-SN38	DMX9ZM4	Breast cancer	2C60-2C65	Phase 2	[22]
Pegamotecan	DMFL96Z	Esophageal cancer	2B70	Phase 2	[23]
Polyglutamate camptothecin	DMXROM7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
TLC-388	DMGWP8L	Solid tumour/cancer	2A00-2F9Z	Phase 2	[24]
XR-5000	DMOKUA5	Colorectal cancer	2B91.Z	Phase 2	[25]
DS-7300	DMK4VY9	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[26]
PEN-866	DMLPTOF	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[27]
ABI-011	DM1KD7U	Lymphoma	2A80-2A86	Phase 1	[28]
Afeletecan	DMNF3GW	Breast cancer	2C60-2C65	Phase 1	[29]
CZ-48	DMAY6X2	Lymphoma	2A80-2A86	Phase 1	[30]
DAN-222	DMJD93K	Breast cancer	2C60-2C65	Phase 1	[31]
Daniquidone	DMWT5RS	Lymphoma	2A80-2A86	Phase 1	[32]
DFP 13318	DMI8QNB	Solid tumour/cancer	2A00-2F9Z	Phase 1	[27]
DRF-1042	DMJY9TW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[33]
DS-6157	DMTKZ1Q	Gastrointestinal stromal tumour	2B5B	Phase 1	[34]
ELOMOTECAN HYDROCHLORIDE	DMQPI4V	Solid tumour/cancer	2A00-2F9Z	Phase 1	[35]
Genz-644282	DMIXABW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[36]
GZ402674	DMTWNLY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[37]
INTOPLICINE	DMXPLMN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[38]
IT-141	DMAYD7O	Solid tumour/cancer	2A00-2F9Z	Phase 1	[27]
LMP400	DM4FW2E	Lymphoma	2A80-2A86	Phase 1	[39]
LMP744	DMUCQYW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[39]
MLN-576	DMCVO2Y	Acute lymphoblastic leukaemia	2A85	Phase 1	[40]
Namitecan	DMMKZYV	Solid tumour/cancer	2A00-2F9Z	Phase 1	[41]
Tafluposide	DMV8IQW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[42]
XMT-1001	DM4MDCH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[43]
(S)-DRF-1042	DMX1ZQV	Bladder cancer	2C94	Clinical trial	[37]

13 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BECATECARIN	DMRQV8I	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 3	[44]
Atiratecan	DMZEMG6	Colorectal cancer	2B91.Z	Discontinued in Phase 2	[45]
Lurtotecan	DMF1RTW	Ovarian cancer	2C73	Discontinued in Phase 2	[46]
NK-611	DM5OVGH	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[47]
S-16020-2	DM51WJN	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[48]
DE-310	DMAOZH3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[49]
BE-13793C	DM6WQ8F	Solid tumour/cancer	2A00-2F9Z	Terminated	[50]
BN-80245	DMMZ9DY	Solid tumour/cancer	2A00-2F9Z	Terminated	[51]
CZ-112	DMF8TCI	Solid tumour/cancer	2A00-2F9Z	Terminated	[30]
Datelliptium chloride	DMR80AL	Breast cancer	2C60-2C65	Terminated	[52]
ED-110	DMJN7MY	Solid tumour/cancer	2A00-2F9Z	Terminated	[53]
PIROXANTRONE	DMR87MO	Solid tumour/cancer	2A00-2F9Z	Terminated	[54]
TAN-1496	DMU3BDY	Solid tumour/cancer	2A00-2F9Z	Terminated	[55]

33 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(5Z,9Z)-5,9-heptacosadienoic acid	DMA97CS	Discovery agent	N.A.	Investigative	[56]
10-hydroxycamptothecin	DM9WLN4	Discovery agent	N.A.	Investigative	[57]
2,3-Dimethoxybenzo[i]phenanthridines	DMEB47J	Discovery agent	N.A.	Investigative	[58]
3,3'-(4-phenylpyridine-2,6-diyl)diphenol	DMJVKMO	Discovery agent	N.A.	Investigative	[59]
3-(4-phenyl-2,4'-bipyridin-6-yl)phenol	DMSZ1VC	Discovery agent	N.A.	Investigative	[59]
3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol	DM0OF64	Discovery agent	N.A.	Investigative	[59]
3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol	DMTR8SZ	Discovery agent	N.A.	Investigative	[59]
3-(6-phenyl-2,4'-bipyridin-4-yl)phenol	DM8ZUBY	Discovery agent	N.A.	Investigative	[59]
4-(4,6-diphenylpyridin-2-yl)phenol	DMETK18	Discovery agent	N.A.	Investigative	[59]
4-(6-phenyl-2,4'-bipyridin-4-yl)phenol	DMJ81IL	Discovery agent	N.A.	Investigative	[59]
4-hydroxysaprothoquinone	DMPIV6J	Discovery agent	N.A.	Investigative	[60]
5-hydroxy-1H-indole-3-acetic acid	DM98OEQ	Discovery agent	N.A.	Investigative	[61]
7-amino-4-hydroxy-2-naphthalenesulfonic acid	DMDUB63	Discovery agent	N.A.	Investigative	[61]
A35566-A	DMFNR3Y	Solid tumour/cancer	2A00-2F9Z	Investigative	[37]
ATI-1150	DMN5VDB	Solid tumour/cancer	2A00-2F9Z	Investigative	[37]
CHO793076	DMZHO3S	Discovery agent	N.A.	Investigative	[62]
CRISNATOL MESILATE	DMY0GXM	Discovery agent	N.A.	Investigative	[63]
Dibenzo-p-dioxin-2-carboxylic acid	DMOKNXE	Discovery agent	N.A.	Investigative	[61]
DTS-108	DM7PNOK	Solid tumour/cancer	2A00-2F9Z	Investigative	[37]
E-758	DMY6DM5	Solid tumour/cancer	2A00-2F9Z	Investigative	[64]
Homocamptothecins (hCPTs)	DMCIRY0	Discovery agent	N.A.	Investigative	[65]
IDN-5174	DMNS9KW	Solid tumour/cancer	2A00-2F9Z	Investigative	[37]
IDN-6384	DM6TEWZ	Solid tumour/cancer	2A00-2F9Z	Investigative	[37]
KT6006	DMXIUO5	Discovery agent	N.A.	Investigative	[66]
KT6528	DMRDZ7I	Discovery agent	N.A.	Investigative	[66]
MEN-14295	DMEIRDX	Solid tumour/cancer	2A00-2F9Z	Investigative	[37]
Nogalamycin	DM50TCG	Discovery agent	N.A.	Investigative	[67]
NSC-341622	DMVGLH7	Discovery agent	N.A.	Investigative	[68]
Quinizarin	DMRQCK3	Discovery agent	N.A.	Investigative	[61]
ROSETTACIN	DMN802V	Discovery agent	N.A.	Investigative	[68]
SER-203	DMIKT7W	Solid tumour/cancer	2A00-2F9Z	Investigative	[37]
TH-1320	DMLC8PX	Solid tumour/cancer	2A00-2F9Z	Investigative	[37]
TOPOSTATIN	DMNZQO9	Discovery agent	N.A.	Investigative	[69]

Molecular Expression Atlas (MEA) of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Lung cancer	2C82	Lung tissue	6.65E-01	0.2	0.39
Rectal cancer	2C82	Rectal colon tissue	1.35E-02	0.37	1.49
Ovarian cancer	2C82	Ovarian tissue	2.65E-01	0.44	0.64
Breast cancer	2C82	Breast tissue	1.05E-01	0.17	0.27
Myelodysplastic syndrome	2C82	Bone marrow	1.09E-01	0.15	0.27
Gastric cancer	2C82	Gastric tissue	1.81E-01	0.79	0.95
Bladder cancer	2C82	Bladder tissue	5.84E-07	0.97	4.96

References

• [1] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [2] Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61.
• [3] Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
• [6] Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021 Dec;20(12):2329-2340.
• [7] Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
• [8] Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014 Dec;74(6):1125-37.
• [9] Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.
• [10] Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9.
• [11] Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9.
• [12] Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin. Ann N Y Acad Sci. 2000;922:178-87.
• [13] Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans. Cancer Chemother Pharmacol. 2014 Jul;74(1):45-54.
• [14] Cancer therapy with beta-lapachone. Curr Cancer Drug Targets. 2002 Sep;2(3):227-42.
• [15] Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res. 1998 Oct;21(5):581-90.
• [16] Company report (Ceruleanrx)
• [17] Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin Investig Drugs. 2009 Jan;18(1):69-75.
• [18] The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. J Chemother. 2010 Jun;22(3):197-200.
• [19] Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect. Biochem Pharmacol. 2013 May 15;85(10):1433-40.
• [20] Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines. Anticancer Res. 2012 Nov;32(11):4823-32.
• [21] Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Discov. 2022 Jan;12(1):74-89.
• [22] EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLoS One. 2012;7(9):e45248.
• [23] A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan;63(2):363-70.
• [24] Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999;56(1):1-12.
• [25] Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80.
• [26] Clinical pipeline report, company report or official report of Daiichi Sankyo.
• [27] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [28] Company report (Indena)
• [29] The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan. Invest New Drugs. 2012 June; 30(3): 1208-1210.
• [30] Pharmacology of camptothecin esters. Ann N Y Acad Sci. 2000;922:216-23.
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [32] Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.Cancer Chemother Pharmacol.2013 Oct;72(4):917-23.
• [33] Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60.
• [34] Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 Jun;11(6):1508-1523.
• [35] The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Ann N Y Acad Sci. 2000;922:303-5.
• [36] Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. Clin Cancer Res. 2011 May 1;17(9):2777-87.
• [37] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636).
• [38] Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol. 1993 Oct;44(4):767-74.
• [39] Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589.
• [40] In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs. 2002 Jan;13(1):15-28.
• [41] Namitecan: a hydrophilic camptothecin with a promising preclinical profile. Curr Med Chem. 2012;19(21):3488-501.
• [42] Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs. 2003 Jul;14(6):467-73.
• [43] Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts. Clin Cancer Res. 2012 May 1;18(9):2591-602.
• [44] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [45] Method development and validation of the simultaneous determination of a novel topoisomerase 1 inhibitor, the prodrug, and the active metabolite in human plasma using column-switching LC-MS/MS, and its application in a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Nov 15;879(30):3415-22.
• [46] Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer. 2004 Apr 1;100(7):1449-58.
• [47] DNA topoisomerase II poisons and inhibitors. Cancer Chemother Biol Response Modif. 1997;17:114-31.
• [48] Cellular resistance to the antitumor DNA topoisomerase II inhibitor S16020-2: importance of the N-[2(Dimethylamino)ethyl]carbamoyl side chain. Mol Pharmacol. 2000 Oct;58(4):709-18.
• [49] DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors. Invest New Drugs. 2005 Aug;23(4):339-47.
• [50] DOI: 10.1002/3527601783.ch20
• [51] BN 80245: An E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorganic & Medicinal Chemistry Letters Volume 7, Issue 17, 9 September 1997, Pages2235-2238.
• [52] Toxicity of the antitumoral drug datelliptium in hepatic cells: Use of models in vitro for the prediction of toxicity in vivo. Toxicol In Vitro. 1992 Jul;6(4):295-302.
• [53] ED-110, a novel indolocarbazole, prevents the growth of experimental tumors in mice. Jpn J Cancer Res. 1993 May;84(5):574-81.
• [54] The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotec... J Inorg Biochem. 1999 Nov-Dec;77(3-4):257-9.
• [55] TAN-1496 A, C and E, diketopiperazine antibiotics with inhibitory activity against mammalian DNA topoisomerase I. J Antibiot (Tokyo). 1994 Nov;47(11):1202-18.
• [56] Total synthesis and biological evaluation of (5Z,9Z)-5,9-hexadecadienoic acid, an inhibitor of human topoisomerase I. J Nat Prod. 2002 Nov;65(11):1715-8.
• [57] Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. Int J Oncol. 1998 Apr;12(4):793-804.
• [58] 2,3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents. Bioorg Med Chem. 2003 Feb 20;11(4):521-8.
• [59] Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.
• [60] Bioactive abietane and seco-abietane diterpenoids from Salvia prionitis. J Nat Prod. 2002 Jul;65(7):1016-20.
• [61] Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking. FEMS Microbiol Lett. 1996 May 1;138(2-3):105-11.
• [62] Synthesis of new camptothecin analogs with improved antitumor activities. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2018-21.
• [63] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [64] Lycobetaine acts as a selective topoisomerase IIbeta poison and inhibits the growth of human tumour cells. Br J Cancer. 2001 November; 85(10): 1585-1591.
• [65] Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit Rev Oncol Hematol. 2003 Jan;45(1):91-108.
• [66] Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry. 1992 Dec 8;31(48):12069-75.
• [67] Structure, dynamics and hydration of the nogalamycin-d(ATGCAT)2Complex determined by NMR and molecular dynamics simulations in solution. J Mol Biol. 1999 Jul 16;290(3):699-716.
• [68] Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of share... Bioorg Med Chem. 2009 Oct 15;17(20):7145-55.
• [69] Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba. J Nat Prod. 2001 Feb;64(2):204-7.